Budget Impact Analysis of Fecal Microbiota Spores, Live-brpk (Formerly SER-109) for Recurrent Clostridioides difficile Infection in the United States

Budget Impact Analysis of Fecal Microbiota Spores, Live-brpk (Formerly SER-109) for Recurrent Clostridioides difficile Infection in the United States

Abstract Introduction Fecal microbiota spores, live-brpk (hereafter VOS) is a microbiota-based orally administered therapeutic approved by the United States Food and Drug Administration for prevention of recurrent Clostridioides difficile infection (rCDI) following standard-of-care (SoC) antibiotics...

Full description

Saved in:
Bibliographic Details
Main Authors: Michele Wilson, Yoav Golan, Dianne Nguyen, Morteza Yazdani, Alpesh N. Amin
Format: Article
Language:English
Published: Adis, Springer Healthcare 2025-07-01
Series:Infectious Diseases and Therapy
Subjects:
Budget impact
Clostridioides difficile infection
Fecal microbiota
Online Access:https://doi.org/10.1007/s40121-025-01169-4
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1007/s40121-025-01169-4

Similar Items